In breast cancer, amplification of HER2 is associated with taxol resistance (Witters et al, 2003), and in glioblastomas increase in EGFr activity to radiation and BCNU (Chakravarti et al, 2002). This evidence concerns the gene ERBB2 and breast cancer.